Literature DB >> 8801209

p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.

P M Rizzi1, S D Ryder, B Portmann, J K Ramage, N V Naoumov, R Williams.   

Abstract

The protein encoded by the p53 tumour suppressor gene plays an important part in the regulation of cell growth. Abnormalities of this gene represent one of the most common genetic changes in the development of human cancers. This study investigated the expression of p53 protein in cholangiocarcinoma arising in association with primary sclerosing cholangitis (PSC). Of the 14 patients with cholangiocarcinoma studied, 13 had underlying PSC. The expression of p53 protein was detected immunohistochemically in paraffin wax embedded liver specimens, after microwave pretreatment. The expression of p53 protein was shown in the cholangiocarcinoma tissue of 11 of 14 (78.5%) patients. In five of 10 patients, the accumulation of p53 protein highlighted the presence of neoplastic cells in biliary tissue separate from the main tumour. These cells were mainly located in the septal bile ducts or in the accessory glands, or both, but occasionally also in large portal areas at the periphery of nerves and lymphatics, and in one case in the mucosa of an extrahepatic bile duct. No p53 protein was detectable in liver tissue obtained at the time of transplantation in 15 patients with PSC but not cholangiocarcinoma. These results show that cholangiocarcinoma development in PSC is commonly associated with abnormalities of p53 and that these occur at a late stage in the development of the malignant process. Staining for p53 protein could represent an additional criterion for the diagnosis of cholangiocarcinoma development in patients with PSC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8801209      PMCID: PMC1383035          DOI: 10.1136/gut.38.2.265

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

Review 1.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

2.  Well-differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters.

Authors:  T Nakajima; Y Kondo
Journal:  Am J Surg Pathol       Date:  1989-07       Impact factor: 6.394

3.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.

Authors:  B Bressac; M Kew; J Wands; M Ozturk
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  J K Ramage; A Donaghy; J M Farrant; R Iorns; R Williams
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

6.  Cholangiocarcinoma complicating primary sclerosing cholangitis.

Authors:  C B Rosen; D M Nagorney; R H Wiesner; R J Coffey; N F LaRusso
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

9.  Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.

Authors:  P L Porter; A M Gown; S G Kramp; M D Coltrera
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

10.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  11 in total

Review 1.  [Pathological anatomical characteristics of Klatskin tumors. Classification, current molecular biological aspects, prognosis factors].

Authors:  J Munding; A Tannapfel
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis.

Authors:  Karouk Said; Hans Glaumann; Mikael Björnstedt; Annika Bergquist
Journal:  Dig Dis Sci       Date:  2012-02-28       Impact factor: 3.199

3.  Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  Johan Fevery; Chris Verslype; Gillian Lai; Raymond Aerts; Werner Van Steenbergen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

Review 4.  Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates.

Authors:  Tarun Rustagi; Constantin A Dasanu
Journal:  J Gastrointest Cancer       Date:  2012-06

5.  Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100).

Authors:  Banchob Sripa; Saman Leungwattanawanit; Takayuki Nitta; Chaisiri Wongkham; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Chongrak Sripa; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

6.  Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver.

Authors:  A Tannapfel; M Benicke; A Katalinic; D Uhlmann; F Köckerling; J Hauss; C Wittekind
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

7.  Pathological aspects of cholangiocarcinoma.

Authors:  I Esposito; P Schirmacher
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

Review 8.  [Palliative therapy of carcinomas of the biliary system].

Authors:  C Lersch; M Classen
Journal:  Med Klin (Munich)       Date:  1997-07-15

9.  Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor).

Authors:  Valerie Byrnes; Nezam Afdhal
Journal:  Curr Treat Options Gastroenterol       Date:  2002-04

10.  Acquisition of Genetic Aberrations by Activation-Induced Cytidine Deaminase (AID) during Inflammation-Associated Carcinogenesis.

Authors:  Atsushi Takai; Hiroyuki Marusawa; Tsutomu Chiba
Journal:  Cancers (Basel)       Date:  2011-06-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.